6489 LOGO20THELANSIS 28

As per a study by CY James et al., there has been a significant increase in the reported annual age-adjusted incidence of NETs from (1.09/100,000) to (5.25/100,000). In 2018, the prevalent population of NETs in the United States was 183,587 and expected to reach 248.367 cases by 2030. The prevalence of NETs in the US is expected to increase at a CAGR of XX% for the study period of 2018-2030. Approximately 58% of NETs patients have GEP sites tumor, 27% lung sites, and 15% other sites. In 2018, there were 39,254 patients suffering from tumors at GEP sites and 18,654 lung sites 8,548 other sites.

Read more:- Neuroendocrine tumors (NETs) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2019 To 2030

 

Neuroendocrine-tumors-NETs

 

Comprehensive insight on patient segmentation based on symptoms (Functional, Non-Functional, Malignant, Non-malignant ), Site Specific (Lungs, GEP sites (Digestive system), Rectum, Jejunum/Ileum, Pancreas, Stomach, Colon, Stage wise (Localized, Regional, Distant), Grade wise ( Grad1NT, Grade 2 NT, Grade 3 NT) has been provided into the epidemiology (Incidence and Prevalence) section of the Neuroendocrine Tumor and its treatment in the 8 MM countries, covering the United States, EU5 (Germany, Spain, France, Italy, UK), Japan, and China

 

KOL database for PMR

 

In terms of pharmacologic therapies, companies like Amgen, Advenchen Laboratories, Antengene, Ignyta, BMS, Mateon, Novartis, Merck, Exelixis, Camurus, EpicentRx, Progenics, Pfizer, ITM, Roche, and Tarveda are in a race to build assets for NET. Companies have shifted their focus towards the development of targeted therapies. Expected launch of potential targeted therapies including potential PD-L1, RTK, VEGF tyrosine kinase inhibitor, Targeted Radionuclide Therapy, Cytotoxic T-lymphocyte antigen 4 inhibitors in Neuroendocrine tumor space. The market is expected to witness rapid growth with the launch of emerging targeted therapies, such as Azedra (Iobenguane I-131) (Progenics Pharmaceuticals), Sulfatinib (Hutchison MediPharma), Axitinib (Pfizer), RRx-001 (EpicentRx), Entrectinib (Ignyta), AMG-479 (Amgen), Carfilzomib (Amgen), Camuru(CAM2029), ATG-008 (Antengene), and Fosbretabulin (Mateon Therapeutics) are likely to get launched by 2025

 

About Thelansis:

Thelansis is specialized in pharmaceutical market research and market Insight Report Company, published reports across the therapeutic area which includes both rare / ultra-rare and mainstream indication. Over the period of time, we have built a strong repository of 6,000+ Bio-pharma reports which essentially covers Epidemiology study and Market forecasting based on the KOL opinions. Competitive intelligence and track of trial results throughout the phases of development executed by a team of a mix of Scientific and Business backgrounds. As an organization, the major focus is to provide real-world data evidence and market insight to pharmaceutical companies for their decision-making.

 

Other Reports:-
Wilson disease (WD) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030

Nasopharyngeal Carcinoma (NPC) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030

Dup15q Syndrome – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030

Desmoid Tumor – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030

Congenital Afibrinogenemia – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030

 

Contact details:-

Gurugram- Onework Gold Souk mall, Phase I, Sector 43, Haryana-122002, India

Contact no.: +91(124) 404-1731

Sales office

183-Asylum Street Hartford, CT-06103, USA

USA +1 (267) 244-6955,

Email

[email protected]

[email protected]

Tags: Neuroendocrine tumors (NETs) market forecast, Neuroendocrine tumors (NETs), Neuroendocrine tumors (NETs) market outlook report, Neuroendocrine tumors (NETs) competitive landscape